# Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

> **NCT07003919** · PHASE3 · RECRUITING · sponsor: **DBV Technologies** · enrollment: 480 (estimated)

## Conditions studied

- Allergy
- Peanut Allergy

## Interventions

- **COMBINATION_PRODUCT:** DBV712 250 mcg
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT07003919
- **Lead sponsor:** DBV Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-24
- **Primary completion:** 2026-11
- **Final completion:** 2028-05
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07003919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07003919, "Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT07003919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*